Heidi, the Melbourne company behind a widely used clinical scribe, has raised $340M through two linked deals. A $100M Series C led by Blackbird values the business at $900M, roughly double what it was worth a year ago. Alongside it, General Catalyst’s Customer Value Fund provided $240M in revenue-based growth capital, repaid out of the sales it funds. Heidi has now raised $436.6M.
The software listens to a consultation and drafts the note, referral and letter that follow. Heidi says it supports about 2.8 million patient encounters a week across 190 countries and 110 languages, and has handled more than 175 million encounters in total.
The product has widened well beyond transcription. Evidence surfaces medical reference material at the point of care and has answered close to eight million queries since spring. A dictation tool works across applications, and Remote is the company’s first piece of hardware.
Most of the compute load runs on Heidi’s own clinical models rather than bought-in frontier systems, a choice that keeps cost and patient data closer to hand. Integrations with electronic health records are deepening, and the company says clinicians keep every clinical decision.
Existing backers Phoenix Court, Point72 Private Investments and Headline joined the round.
Why it matters. Ambient documentation is the most crowded corner of healthcare AI, and a scribe is easy to copy. Heidi’s defense is distribution and workflow depth rather than model quality. The growth capital is aimed squarely at sales, which suggests the next phase of the race will be fought over health system contracts rather than benchmarks.
